A 35-year-old man with no significant medical history presented to a university ED complaining of anxiety. tremors and insomnia. The patient denied use of common street drugs or tobacco. He admitted to social weekend alcohol consumption, but had not been drinking during the preceding 2 weeks. His vital signs were: temperature 37.2OC, pi~lse 105/min. respirations 161 min. blood pressure 148188 mmHg. Physical examination revealed a muscular young man with a resting tremor and obvious anxiety. but was otherwise unremarkable. The patient's girlfriend took the physician aside and revealed the actual reason for seeking ED treatment was that he was trying to quit using GHB. She also confirmed he had nor been drinking alcohol and was not a habitual alcohol user. The patient subsequently admitted to using increasing amounts of GHB for the previous 2.5 years, and was consuming 1 to 2 "capfuls" of liquid GHB 4 to 6 times daily (exact dose unknown). His last dose was 20 hours prior to presentation. The patient first started using GHB at the urging of weight-lifting friends. He had attempted to quit multiple times without success. A presumptive diagnosis of GHB withdrawal was made. The patient was treated with 20 mg of oral diazepam in the ED, which relieved the tremors. After a 3-hour observation period. he was discharged with a 3-day prescription for lorazepam. referred to a local primary care clinic and given substance abuse counseling information.
Clirlical Marl(festc~tions
GHB is a naturally occurring substance. found in highest concentrations in the basal ganglia and hypothalamus of brain tissue.' Although commercial sale of GHB is illegal in the United States. it is still easy to obtain, as evidenced by its abundance at rave parties. GHB recipes and various precursor formulations containing gamma-butyrolactone, 1.4-butanediol, dihydro-2(3H)-furanone and 4-butanolide are also available via the internet.? The precursors are converted in vivo to GHB after ingestion. GHB is popular among rave crowds and body-builders. and has been implicated as a "date-rape" drug. Investigational narcolepsy treatment is the only FDA approved use for GHB in the United States.
As GHB use has increased because of its sedative. eupage 16 phoric and purported anabolic effects, a clinical GHB withdrawal syndrome has emerged among habitual users. The habit-forming nature of GHB and a description of clinical features associated with abruptly stopping or decreasing use was first noted in 1994.' A withdrawal syndrome is characterized by various expectant psychological andlor physical signs and symptoms caused by the abrupt cessation of a drug that is used habitually. Given the ~nultiple independent descriptions of similar signs and symptoms associated with the cessation of chronic GUB use. GUB is now considered to possess a true withdrawal syndrome."" Based on these case series and reports, the signs and symptoms of GHB withdrawal include varying degrees of anxiety. agitation. and insomnia. Ophthalrnoplegia with sixth cranial nerve palsies has been reported in association with GHB withdrawal, although this niay represent concomitant thiamine deficiency. Autonomic hyperactivity manifesting as diaphoresis, tremors. tachycardia or elevated blood pressure is commonly reported. Behavioral and psychiatric features include paranoia, hallucinations (auditory and/ or visual) and delirium. Syn~ptoms may manifest as soon as 12 hours after last use and may last LIP to 12 days. It is believed that more severe symptoms occur in individuals with longer habits and in those taking larger amounts of CHB. Many patients will also have a history of prior GHB cessation failure^.^
The largest report of cases implicating a physical dependence to GHB came from Italian researchers using GHB for treatment of alcohol dependence.' Eleven patients (10% of subjects completing a 24 week protocol of t.i.d. dosing of 50rngIkg CHB) developed "cravings" for the drug and voluntarily increased their doses to achieve ailxiolytic and hypnotic effects. The authors noted that anxiety and insomnia were reported after decreasing the GHB doses. which likely represented mild GHB withdrawal.
Sii?zilarih to Ofher Withcirawal Syflch-ortles
GHB withdrawal appears to be very similar to ethanol, benzodiazepine (BZD) and barbiturate withdrawal. This similarity is likely related to GHB's chemical structural similarity with GABA. the principle inhibitory CNS neurotransmitter. GHE exhibits a marked affinity for the GABA, receptor. compared to the GABA, receptor, as well as an affinity for a recently discovered CHB-specific receptor. An extensive review of the neuropharmacology of GHB by TunnicliH reveals that low doses of CHB tend to inhibit CNS dopamine release, whereas in higher and sustained doses. analogous to a habitual user, CNS dopamine levels increase. A decrease or total cessation of the dependent drug is all that is needed to precipitate the clinical withdrawal, a feature common to many sedative-hypnotic agents. Table 1 shows the time course of symptoms for the withdrawal syndromes from GHB and some other substances of abuse. Autoi~omic hyperactivity is common in CNS depressant withdrawals, with symptoms ranging from mild tachycardia and tremor to extreme diaphoresis and elevated blood pressure. Seizures have not been reported to occur in GHB withdrawal, however, the number of case reports is relatively small. Aside froin seizures, no other clinical feature reliably distinguishes GHB withdrawal froin the other sedative-hypnotic withdrawal syndromes. Thus, obtaining a truthful history from the patient, a close friend or relatives is crucial.
For patients who openly adinit to habitual CHB use, the diagnosis is straightforward. However, for patients with the myriad of symptoms which by themselves are not diagnostic or pathognomonic, making the diagnosis and initiating treatment can be challenging. Negative urine or serum toxicology screens for other comrnon drugs of abuse can be useful in making the diagnosis. GMB, however, is not detected by routine drug tests. Specific serum or urine testing for GHB is not generally indicated and is not widely available. except at regional specialty labs. There .!ppears to be cross-reactivity of GHB with ethanol, BZDs and opiates, which may explain why many patients coingest these other substances, perhaps in an attempt to offset the withdrawal symptoms."-"" GWB has been used successfully for over a decade in Europe to treat opioid and alcohol dependence."" lending fitsther support to the notion of pharmacological crosstolerance among these CNS depressants.
Treutmeltr Options
Clinically. patients respond well to BZD treatment and supportive measures while other diagnoses are worked up and excluded. Table 2 summarizes the various medications that have been reported as useful for GHB withdrawal. Case reports indicate that the best results are achieved using a benzodiazepine, alone or in combirtation with an antipsychotic agent. Inter~nedi-ate-to long-acting BZDs are emerging as the first-line treatment of choice: 20mg oral diazepam or 4mg oral lorazepam is a suggested starting dose. Massive amounts of sedatives (507mg lorazepam and 120mg diazepam in one patient over 90h) have been reported in one case series9 Behavioral and psychotic features of GHB withdrawal respond to antipsychotic medications. Referral to outpatient substance abuse and support groups is recommended. Patients with severe withdrawal features, hemodynamic instability, florid psychosis or those requiring large doses of medication to control symptoms should be admitted to an appropriate monitored unit for continuous cardiopulmonary and neurologic monitoring. 
Sumnzary
Habitual ingestion of GHB has been associated with a withdrawal syndrome consisting of autonomic hyperactivity and various behavioral and psychotic features when the drug is stopped or the dose is decreased. The description of a GHB withdrawal syndrome is based on multiple, independent descriptions of similar clinical presentations in patients with admitted or confirmed GHB habitual use. GHB withdrawal is similar to other sedative-hypnotic withdrawal syndromes. The popularity of CHB with the rave crowd and body-builders is increasing. Emergency physicians need to be aware of the signs and symptoms associated both with GHB intoxication and with GHB withdrawal. Benzodiazepines are first-line treatment for mild GHB withdrawal; severe cases with unstable vital signs or florid psychosis should be treated in an inpatient setting. most were found to present with symptoms of headache, fever, vomiting. seizures. and disorientation during the summer months. Ten percent of children developed a complicated course includirlg intubation and ICU care. Although all children survived, 12% overall had significant permanem neuro!ogic problems including decreased IQ. paralysis, memory loss and behavioral changes or cerebral dysfunction
